Esclerosis Múltiple / Multiple Sclerosis

Volver a Principal

Instituciones Lideres en los últimos diez años ( Sólo publicaciones en la coleccion Core Clínical Journals)

Bibliografía en Revistas Internaciones de Instituciones Españolas en los últimos diez años.

 

The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis.
J Neuroimmunol. 2012 Feb 29;243(1-2):1-11. Epub 2012 Jan 20. Pinto-Medel M.J., Garcia-Leon J.A., Oliver-Martos B., Lopez-Gomez C., Luque G., Arnaiz-Urrutia C., Orpez T., Marin-Banasco C., Fernandez O., Leyva L.

High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis.
Mult Scler. 2011 Nov;17(11):1295-300. Epub 2011 Jul 14. Santon A., Cristobal E., Aparicio M., Royuela A., Villar L.M., Alvarez-Cermeno J.C.

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.
Clin Immunol. 2011 Dec;141(3):348-56. Epub 2011 Sep 21. Martinez-Rodriguez J.E., Lopez-Botet M., Munteis E., Rio J., Roquer J., Montalban X., Comabella M.

Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis.
J Neuroimmunol. 2012 Mar;244(1-2):103-6. Epub 2012 Jan 14. Boronat A., Sepulveda M., Llufriu S., Sabater L., Blanco Y., Gabilondo I., Sola N., Villoslada P., Dalmau J., Graus F., Saiz A.

Neuroprotective agents: cannabinoids.
Clin Immunol. 2012 Jan;142(1):57-67. doi: 10.1016/j.clim.2011.02.010. Epub 2011 Mar 21. Sanchez A.J., Garcia-Merino A.

Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation.
Clin Immunol. 2012 Jan;142(1):84-92. doi: 10.1016/j.clim.2011.06.004. Epub 2011 Jun 25. Espejo C., Montalban X.

Immunopathogenesis of multiple sclerosis.
Clin Immunol. 2012 Jan;142(1):2-8. doi: 10.1016/j.clim.2011.03.004. Epub 2011 Mar 12. Comabella M., Khoury S.J.

Risk factors for progressive axonal degeneration of the retinal nerve fibre layer in multiple sclerosis patients.
Br J Ophthalmol. 2011 Nov;95(11):1577-82. Epub 2011 Jul 23. Garcia-Martin E., Pueyo V., Almarcegui C., Martin J., Ara J.R., Sancho E., Pablo L.E., Dolz I., Fernandez J.

Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
Arch Neurol. 2011 Nov;68(11):1421-7. Tur C., Montalban X., Tintore M., Nos C., Rio J., Aymerich F.X., Brieva L., Tellez N., Perkal H., Comabella M., Galan I., Calle D., Sastre-Garriga J., Rovira A.

Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis.
J Neuroinflammation. 2011 Nov 2;8:149. Virgili N., Espinosa-Parrilla J.F., Mancera P., Pasten-Zamorano A., Gimeno-Bayon J., Rodriguez M.J., Mahy N., Pugliese M.

IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.
J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. Epub 2011 Sep 1. Malhotra S., Morcillo-Suarez C., Brassat D., Goertsches R., Lechner-Scott J., Urcelay E., Fernandez O., Drulovic J., Garcia-Merino A., Martinelli B., Chan A., Vandenbroeck K., Navarro A., Bustamante M.F., Rio J., Akkad D.A., Giacalone G., Sanchez A.J., Leyva L., Alvarez-Lafuente R., Zettl U.K., Oksenberg J., Montalban X., Comabella M.

Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab.
J Neuroimmunol. 2012 Feb 29;243(1-2):103-5. Epub 2012 Jan 5. Mulero P., Caminero A.B., Neri C., Fernandez-Herranz R., Tellez L.

Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.
Clin Exp Immunol. 2011 Dec;166(3):338-45. doi: 10.1111/j.1365-2249.2011.04484.x. Caminero A., Comabella M., Montalban X.

Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.
Neuroradiology. 2012 Jan;54(1):5-12. Epub 2011 Feb 16. Magraner M.J., Bosca I., Simo-Castello M., Garcia-Marti G., Alberich-Bayarri A., Coret F., Alvarez-Cermeno J.C., Marti-Bonmati L., Villar L.M., Casanova B.

Gain-of-function of P2X7 receptor gene variants in multiple sclerosis.
Cell Calcium. 2011 Nov;50(5):468-72. doi: 10.1016/j.ceca.2011.08.002. Epub 2011 Sep 8. Oyanguren-Desez O., Rodriguez-Antiguedad A., Villoslada P., Domercq M., Alberdi E., Matute C.

Association between environmental exposure to pesticides and neurodegenerative diseases.
Toxicol Appl Pharmacol. 2011 Nov 1;256(3):379-85. Epub 2011 May 13. Parron T., Requena M., Hernandez A.F., Alarcon R.

Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis.
Brain Pathol. 2011 Nov;21(6):678-91. doi: 10.1111/j.1750-3639.2011.00495.x. Epub 2011 Jun 9. Moline-Velazquez V., Cuervo H., Vila-Del S., Ortega M.C., Clemente D., de C.

DNA-based vaccines for multiple sclerosis: current status and future directions.
Clin Immunol. 2012 Jan;142(1):76-83. doi: 10.1016/j.clim.2010.11.011. Epub 2010 Dec 15. Fissolo N., Montalban X., Comabella M.

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Mult Scler. 2011 Nov;17(11):1341-50. Epub 2011 Jul 4. Montalban X., Comi G., O'Connor P., Gold S., de V., Eckert B., Kappos L.

Immunological markers of optimal response to natalizumab in multiple sclerosis.
Arch Neurol. 2012 Feb;69(2):191-7. Villar L.M., Garcia-Sanchez M.I., Costa-Frossard L., Espino M., Roldan E., Paramo D., Lucas M., Izquierdo G., Alvarez-Cermeno J.C.

Subir